# Osteoporosis â€“ Bone Ossification Enhancers

This is a subcategory of Endocrine Agents.

## Formulary

### Preferred

| Preferred         | Generic Name | Quantity | Time (Days) |
| :---------------- | :----------- | :------: | :---------: |
| Alendronate Tab   |              |          |             |
| Calcitonin-Salmon |              |          |             |
| Forteo <sup>QL</sup>           |              |          |             |
| Ibandronate       |              |          |             |

### Non-Preferred

| Non-Preferred    | Generic Name | Quantity | Time (Days) |
| :--------------- | :----------- | :------: | :---------: |
| Alendronate Susp |              |          |             |
| Fosamax Plus D   |              |          |             |
| Risedronate      |              |          |             |
| Tymlos <sup>QL</sup>          |              |          |             |

## Length of Authorizations

365 Days

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **365 days** with at least **one preferred** drug within the same drug class
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Abaloparatide (Tymlos <sup>TM</sup>)

Additional Abaloparatide (Tymlos <sup>TM</sup>) Criteria

Must have had an inadequate clinical response of at least **365 days** with **one** bisphosphonate

## Additional Information

- Patients should only be on ONE of the therapeutic classes (bisphosphonates, calcitonin-salmon)
- A total lifetime duration of therapy of 730 days with any parathyroid analog will be authorized

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=59)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=13)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
